Photoreceptor degeneration in ABCA4-associated retinopathy and its genetic correlates.
ATP-Binding Cassette Transporters
/ genetics
Age Factors
Deep Learning
Disease Progression
Electroretinography
/ methods
Female
Follow-Up Studies
Genetic Association Studies
/ methods
Humans
Male
Middle Aged
Photoreceptor Cells, Vertebrate
/ metabolism
Retina
/ diagnostic imaging
Retinal Degeneration
/ diagnosis
Rod Cell Outer Segment
/ metabolism
Severity of Illness Index
Tomography, Optical Coherence
/ methods
Genetic diseases
Ophthalmology
Retinopathy
Journal
JCI insight
ISSN: 2379-3708
Titre abrégé: JCI Insight
Pays: United States
ID NLM: 101676073
Informations de publication
Date de publication:
25 01 2022
25 01 2022
Historique:
received:
28
09
2021
accepted:
01
12
2021
entrez:
25
1
2022
pubmed:
26
1
2022
medline:
23
3
2022
Statut:
epublish
Résumé
BACKGROUNDOutcome measures sensitive to disease progression are needed for ATP-binding cassette, sub-family A, member 4-associated (ABCA4-associated) retinopathy. We aimed to quantify ellipsoid zone (EZ) loss and photoreceptor degeneration beyond EZ-loss in ABCA4-associated retinopathy and investigate associations between photoreceptor degeneration, genotype, and age.METHODSWe analyzed 132 eyes from 66 patients (of 67 enrolled) with molecularly confirmed ABCA4-associated retinopathy from a prospective natural history study with a median [IQR] follow-up of 4.2 years [3.1, 5.1]. Longitudinal spectral-domain optical coherence tomography volume scans (37 B-scans, 30° × 15°) were segmented using a deep learning (DL) approach. For genotype-phenotype analysis, a model of ABCA4 variants was applied with the age of criterion EZ-loss (6.25 mm2) as the dependent variable.RESULTSPatients exhibited an average (square-root-transformed) EZ-loss progression rate of [95% CI] 0.09 mm/y [0.06, 0.11]. Outer nuclear layer (ONL) thinning extended beyond the area of EZ-loss. The average distance from the EZ-loss boundary to normalization of ONL thickness (to ±2 z score units) was 3.20° [2.53, 3.87]. Inner segment (IS) and outer segment (OS) thinning was less pronounced, with an average distance from the EZ-loss boundary to layer thickness normalization of 1.20° [0.91, 1.48] for the IS and 0.60° [0.49, 0.72] for the OS. An additive model of allele severity explained 52.7% of variability in the age of criterion EZ-loss.CONCLUSIONPatients with ABCA4-associated retinopathy exhibited significant alterations of photoreceptors outside of EZ-loss. DL-based analysis of photoreceptor laminae may help monitor disease progression and estimate the severity of ABCA4 variants.TRIAL REGISTRATIONClinicalTrials.gov identifier: NCT01736293.FUNDINGNational Eye Institute Intramural Research Program and German Research Foundation grant PF950/1-1.
Identifiants
pubmed: 35076026
pii: 155373
doi: 10.1172/jci.insight.155373
pmc: PMC8855828
doi:
pii:
Substances chimiques
ABCA4 protein, human
0
ATP-Binding Cassette Transporters
0
Banques de données
ClinicalTrials.gov
['NCT01736293']
Types de publication
Journal Article
Observational Study
Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Mol Ther Nucleic Acids. 2020 Sep 4;21:412-427
pubmed: 32653833
Retina. 2021 Dec 1;41(12):2578-2588
pubmed: 34125082
Sci Rep. 2021 Jan 14;11(1):1466
pubmed: 33446864
Hum Mol Genet. 2004 Mar 1;13(5):525-34
pubmed: 14709597
Genome Res. 2018 Jan;28(1):100-110
pubmed: 29162642
Ophthalmology. 2016 Jun;123(6):1375-85
pubmed: 26976702
Invest Ophthalmol Vis Sci. 2000 Sep;41(10):3200-9
pubmed: 10967084
Invest Ophthalmol Vis Sci. 2016 Dec 1;57(15):6824-6830
pubmed: 28002570
Hum Mol Genet. 2021 Jun 26;30(14):1293-1304
pubmed: 33909047
Eye (Lond). 2019 Nov;33(11):1683-1698
pubmed: 31164730
JAMA Ophthalmol. 2017 Nov 1;135(11):1232-1241
pubmed: 29049437
Nat Genet. 1997 Mar;15(3):236-46
pubmed: 9054934
Graefes Arch Clin Exp Ophthalmol. 2019 Mar;257(3):549-556
pubmed: 30613916
JAMA Ophthalmol. 2020 Oct 1;138(10):1035-1042
pubmed: 32815999
Am J Ophthalmol. 2021 Feb;222:340-350
pubmed: 32891696
Invest Ophthalmol Vis Sci. 2018 Mar 20;59(4):AMD122-AMD131
pubmed: 30140905
Invest Ophthalmol Vis Sci. 2020 Apr 9;61(4):36
pubmed: 32334431
Invest Ophthalmol Vis Sci. 2019 Sep 3;60(12):3992-4001
pubmed: 31560765
Sci Rep. 2020 Oct 6;10(1):16576
pubmed: 33024232
Am J Ophthalmol. 2018 Feb;186:1-9
pubmed: 29126757
Genet Med. 2020 Jul;22(7):1235-1246
pubmed: 32307445
Invest Ophthalmol Vis Sci. 2013 Apr 17;54(4):2812-20
pubmed: 23548623
JAMA Ophthalmol. 2019 Oct 1;137(10):1134-1145
pubmed: 31369039
J Clin Med. 2020 Jul 29;9(8):
pubmed: 32751377
JAMA Ophthalmol. 2013 Sep;131(9):1143-50
pubmed: 23828615
Transl Vis Sci Technol. 2019 Mar 1;8(2):1
pubmed: 30834176
Am J Ophthalmol. 2013 Jun;155(6):1075-1088.e13
pubmed: 23499370
Retina. 2020 Dec;40(12):2343-2356
pubmed: 33214501
Ophthalmology. 2019 Sep;126(9):1288-1296
pubmed: 31227323
Ophthalmology. 2015 Feb;122(2):335-44
pubmed: 25444351
Hum Mol Genet. 2015 Jun 1;24(11):3220-37
pubmed: 25712131
Transl Vis Sci Technol. 2018 Oct 1;7(5):13
pubmed: 30279998
Hum Mol Genet. 2009 Mar 1;18(5):931-41
pubmed: 19074458
Invest Ophthalmol Vis Sci. 2009 Dec;50(12):5867-71
pubmed: 19578016
Invest Ophthalmol Vis Sci. 2015 Sep;56(10):5946-55
pubmed: 26377081
JAMA Ophthalmol. 2013 Jan;131(1):110-1
pubmed: 23307222
Invest Ophthalmol Vis Sci. 2005 Dec;46(12):4739-46
pubmed: 16303974
Invest Ophthalmol Vis Sci. 2016 Oct 1;57(13):5186-5191
pubmed: 27699414
Am J Hum Genet. 1999 Feb;64(2):422-34
pubmed: 9973280
Invest Ophthalmol Vis Sci. 2012 Sep 14;53(10):6145-52
pubmed: 22899757
Invest Ophthalmol Vis Sci. 2014 May 01;55(5):2841-52
pubmed: 24677105
JAMA Ophthalmol. 2020 Oct 1;138(10):1026-1034
pubmed: 32789526
Curr Eye Res. 2015 Apr;40(4):398-406
pubmed: 24912073
Invest Ophthalmol Vis Sci. 2016 Nov 1;57(14):5963-5973
pubmed: 27820952